| Market Closed - Nasdaq Other stock markets | 5-day change | 1st Jan Change | ||
| 23.2 USD | -0.39% |  | +4.79% | +21.21% |
| 06-12 | Transcript : Myriad Genetics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 03:20 PM | |
| 06-11 | Myriad Genetics, GSK Partner to Expand Access to HRD Diagnostic Testing | MT |
Presenter SpeechMatthew Sykes (Analysts)Thanks for joining us today. I'm Matt Sykes, Life Scie...
This article is reserved for subscribers
Signed up already?
Log In
Not subscribed yet?
Subscribe
Latest news about Myriad Genetics, Inc.
| Transcript : Myriad Genetics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 03:20 PM | ||
| Myriad Genetics, GSK Partner to Expand Access to HRD Diagnostic Testing | MT | |
| Qiagen, Myriad Genetics Team Up to Develop hom*ologous Recombination Deficiency Test | MT | |
| Qiagen, Myriad Genetics Partner to Create Easily Distributable Cancer Tumor Test | MT | |
| QIAGEN and Myriad Genetics Develop Distributable hom*ologous Recombination Deficiency Test for Global Research and Companion Diagnostics Applications | CI | |
| Transcript : Myriad Genetics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 05:15 PM | ||
| Piper Sandler Adjusts Price Target on Myriad Genetics to $28 From $23, Maintains Neutral Rating | MT | |
| Sector Update: Health Care Stocks Softer Late Afternoon | MT | |
| Myriad Genetics Shares Rise After Reporting Narrower Q1 Adjusted Loss, Higher Revenue | MT | |
| Eurobio Scientific: agreement with Myriad Genetics | CF | |
| Eurobio Scientific to Buy Gene Expression Test for Breast Cancer | MT | |
| Earnings Flash (MYGN) MYRIAD GENETICS Reports Q1 Revenue $202.2M, vs. Street Est of $193.3M | MT | |
| (MYGN) MYRIAD GENETICS Sees Fiscal Year 2024 EPS Range $0.00 - $0.05 | MT | |
| (MYGN) MYRIAD GENETICS Sees Fiscal Year 2024 Revenue Range $820M - $840M | MT | |
| Myriad Genetics to Seek Acquisitions | CI | |
| Transcript : Myriad Genetics, Inc., Q1 2024 Earnings Call, May 07, 2024 | ||
| Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full Year 2024 | CI | |
| Myriad Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI | |
| Eurobio Scientific Société anonyme signed a definitive agreement to acquire EndoPredict business of Myriad Genetics, Inc for $10 million. | CI | |
| Myriad Genetics Gets US Patent for SneakPeek Snap Device | MT | |
| Transcript : Myriad Genetics, Inc., Q4 2023 Earnings Call, Feb 27, 2024 | ||
| Earnings Flash (MYGN) MYRIAD GENETICS Reports Q4 EPS $0.04, vs. Street Est of $0.01 | MT | |
| (MYGN) MYRIAD GENETICS Forecasts 2024 Revenue Range $820M - $840M | MT | |
| Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024 | CI | |
| Myriad Genetics, Inc. Updates Revenue Guidance for the Fiscal Year 2024 | CI |
Chart Myriad Genetics, Inc.
More charts
Company Profile
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Companyâs testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight.
Sector
Calendar
31/07/2024 - Q2 2024 Earnings Release (Projected)
Related indices
Russell 2000
More about the company
Income Statement Evolution
More financial data
Ratings for Myriad Genetics, Inc.
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Analysts' Consensus
Sell
Buy
Mean consensus
HOLD
Number of Analysts
11
Last Close Price
23.2USD
Average target price
25.09USD
Spread / Average Target
+8.15%
Consensus
EPS Revisions
Estimates Revisions
Quarterly earnings - Rate of surprise
Company calendar
| 1st Jan change | Capi. | |
|---|---|---|
MYRIAD GENETICS, INC. | +21.21% | 2.1B |
BIOMÉRIEUX | -9.74% | 11.48B |
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. | -9.80% | 7.64B |
LANTHEUS HOLDINGS, INC. | +27.84% | 5.49B |
AUTOBIO DIAGNOSTICS CO., LTD. | -15.47% | 3.86B |
ANDON HEALTH CO., LTD. | +8.47% | 2.61B |
10X GENOMICS, INC. | -63.81% | 2.42B |
VITROLIFE AB | -9.24% | 2.27B |
GUANGZHOU WONDFO BIOTECH CO.,LTD | -9.38% | 1.76B |
SANSURE BIOTECH INC. | -7.16% | 1.43B |
- Stock Market
- Equities
- MYGN Stock
- News Myriad Genetics, Inc.
- Transcript : Myriad Genetics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 03
